Literature DB >> 3604753

Fasting, postprandial and postprandial plus glucagon-stimulated plasma C-peptide levels in non-insulin-dependent diabetics and in control subjects.

H Sarlund, M Laakso, K Pyörälä, I Penttilä.   

Abstract

We have studied fasting, postprandial and postprandial plus glucagon-stimulated plasma C-peptide levels in 149 non-insulin-dependent diabetics treated either with diet or oral drugs and in 101 non-diabetic control subjects. Diet-treated diabetics showed the highest fasting, postprandial and post-glucagon C-peptide levels in both sexes. In men, diabetics treated with oral drugs showed lower postprandial and glucagon-stimulated C-peptide levels than control subjects, while in women C-peptide levels in this group of diabetics were similar to those in control subjects. The distribution of individual plasma C-peptide levels was wide in non-insulin-dependent diabetics and control subjects and there was considerable overlapping in plasma C-peptide distribution for diabetics and control subjects. Fasting and post-glucagon plasma C-peptide levels in diabetics showed an inverse association to plasma glucose levels and a positive association to degree of obesity, but no association with the known duration of diabetes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3604753     DOI: 10.1111/j.0954-6820.1987.tb03359.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  2 in total

1.  Arginine is preferred to glucagon for stimulation testing of β-cell function.

Authors:  R Paul Robertson; Ralph H Raymond; Douglas S Lee; Roberto A Calle; Atalanta Ghosh; Peter J Savage; Sudha S Shankar; Maria T Vassileva; Gordon C Weir; David A Fryburg
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-26       Impact factor: 4.310

2.  Serum C-peptide assay of patients with hyperglycemic emergencies at the Lagos State University Teaching Hospital (LASUTH), Ikeja.

Authors:  Akinyele Taofiq Akinlade; Anthonia Okeoghene Ogbera; Olufemi Adetola Fasanmade; Michael Adeyemi Olamoyegun
Journal:  Int Arch Med       Date:  2014-11-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.